BUZZ-Acorda Therapeutics plunges on Chapter 11 bankruptcy filing

Reuters04-02

** Shares of drugmaker Acorda Therapeutics fall 64.88% to $4.73 premarket- top pct. loser across U.S. exchanges

** Co files for Chapter 11 bankruptcy protection

** ACOR entered into an asset purchase agreement with Germany based Merz Therapeutics to buy substantially all of the assets of Acorda, including rights to its drugs Inbrija, Ampyra and Fampyra for $185 million

** Patient access to the Parkinson's disease treatment Inbrija and Ampyra, which helps to improve walking in adults with multiple sclerosis, to continue uninterrupted - ACOR

** Co will continue operations while it works to complete the sale process

** Up to last close, stock down ~11% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424094853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-02 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424094853","market":"us","top_or_hot":-1,"title":"BUZZ-Acorda Therapeutics plunges on Chapter 11 bankruptcy filing","media":"Reuters","content":"<html><body><p>** Shares of drugmaker Acorda <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>    fall 64.88% to $4.73 premarket- top pct. loser across U.S. exchanges</p><p>   ** Co files for Chapter 11 bankruptcy protection</p><p>   ** ACOR entered into an asset purchase agreement with Germany based Merz Therapeutics to buy substantially all of the assets of Acorda, including rights to its drugs Inbrija, Ampyra and Fampyra for $185 million</p><p>   ** Patient access to the Parkinson's disease treatment Inbrija and Ampyra, which helps to improve walking in adults with multiple sclerosis, to continue uninterrupted - ACOR</p><p>   ** Co will continue operations while it works to complete the sale process</p><p>   ** Up to last close, stock down ~11% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p>((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Acorda Therapeutics plunges on Chapter 11 bankruptcy filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Acorda Therapeutics plunges on Chapter 11 bankruptcy filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-02 18:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of drugmaker Acorda Therapeutics    fall 64.88% to $4.73 premarket- top pct. loser across U.S. exchanges   ** Co files for Chapter 11 bankruptcy protection   ** ACOR entered into an asset ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACOR","symbol_name":"阿索尔达生物制药公司","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424094853","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424094853","pubTimestamp":1712053673,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of drugmaker Acorda Therapeutics    fall 64.88% to $4.73 premarket- top pct. loser across U.S. exchanges   ** Co files for Chapter 11 bankruptcy protection   ** ACOR entered into an asset purchase agreement with Germany based Merz Therapeutics to buy substantially all of the assets of Acorda, including rights to its drugs Inbrija, Ampyra and Fampyra for $185 million   ** Patient access to the Parkinson's disease treatment Inbrija and Ampyra, which helps to improve walking in adults with multiple sclerosis, to continue uninterrupted - ACOR   ** Co will continue operations while it works to complete the sale process   ** Up to last close, stock down ~11% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACOR":"阿索尔达生物制药公司","BUZZ":"VanEck Social Sentiment ETF","BK4139":"生物科技","BK4568":"美国抗疫概念"},"translate_title":"BUZZ-Acorda Therapeutics陷入第11章破产申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACOR":1,"BUZZ":1},"content_text":"** Shares of drugmaker Acorda Therapeutics    fall 64.88% to $4.73 premarket- top pct. loser across U.S. exchanges   ** Co files for Chapter 11 bankruptcy protection   ** ACOR entered into an asset purchase agreement with Germany based Merz Therapeutics to buy substantially all of the assets of Acorda, including rights to its drugs Inbrija, Ampyra and Fampyra for $185 million   ** Patient access to the Parkinson's disease treatment Inbrija and Ampyra, which helps to improve walking in adults with multiple sclerosis, to continue uninterrupted - ACOR   ** Co will continue operations while it works to complete the sale process   ** Up to last close, stock down ~11% YTD (Reporting by Sriparna Roy in Bengaluru)((Sriparna.Roy@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424094853"}